ICML 2013

 
 
 

The 12th International Conference on Malignant Lymphoma took place June 19-22, 2013, in Lugano, Switzerland.

 

Romidepsin plus CHOP feasible in PTCL

Erilyn Riley Read Article
Published: 07/02/13

Dupuis_Jehan_MD_12-ICML_240.jpg
Jehan Dupuis, MD

Combining the HDAC inhibitor romidepsin with CHOP chemotherapy is feasible, but the regimen can elicit “foreseeable hematological toxicity,” according to an interim analysis presented at 12-ICML. Romidepsin is FDA approved for relapsed/refractory peripheral T-cell lymphoma (PTCL) and has achieved an overall response rate up to 38% in recurrent/refractory PTCL. Investigators sought to improve this response rate by combining romidepsin . . .  [Read Article]

After shaky start, ABT-199 back on track

Erilyn Riley Read Article
Published: 06/28/13

Seymour_John_ICML_2013_240_v2.jpg
John Seymour, MD

The first-in-human study of the BCL-2 inhibitor ABT-199 is showing “dramatic efficacy” in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to an update presented at 12-ICML. And this comes after a shaky start: accrual had been suspended earlier this year because of tumor lysis syndrome. “Accrual of this study was put on hold for a number of months,” said John F. Seymour, MD, “and discussion with the FDA led to modifications . . .  [Read Article]

Increased risk of diabetes observed in HL survivors

Erilyn Riley Read Article
Published: 06/27/13

radiation_therapy_patient_receiving_Credit_Sue_Campbell_230.jpg
Patient receiving radiation
Credit: Sue Campbell

Survivors of Hodgkin lymphoma who received their first treatment between 1965 and 1995 are at an increased risk of developing diabetes mellitus, according to new research presented at 12-ICML. The 30-year cumulative incidence was 11.1% for 5-year survivors who had radiation to the spleen or splenic hilum, compared to 6.2% of patients who had no para-aortic (PAO) or splenic radiation. And this has implications for the care of long-term survivors, said Berthe M. Aleman, MD . . .  [Read Article]

‘Respectable’ outcomes with idelalisib in combination

Erilyn Riley Read Article
Published: 06/26/13

Leonard_John_P_MD_ICML-12_240.jpg
John P. Leonard, MD

A phase 1 trial of idelalisib in combination with rituximab, bendamustine, or both revealed “quite respectable” outcomes in patients with indolent non-Hodgkin lymphoma (iNHL), according to a speaker at 12-ICML. John P. Leonard, MD, of Weill Cornell Medical College in New York, presented these results at the meeting as abstract 068. He noted, however, that the trial was not randomized, and the comparative regimens were investigator’s choice. [Read Article]

Idelalisib demonstrates importance of PI3K delta pathway

Erilyn Riley Read Article
Published: 06/26/13

Salles_Gilles_MD_ICML-12_240.jpg
Gilles Salles, MD

Two studies of idelalisib presented at 12-ICML in Lugano, Switzerland, underscored the importance of the PI3K delta pathway in B-cell lymphoma. Both studies were conducted in refractory indolent non-Hodgkin lymphoma (iNHL) patients, one as monotherapy and the other in combination with rituximab, bendamustine, or both drugs. Idelalisib is a highly selective, oral inhibitor of the PI3K delta pathway. It has little or no activity in the other isoforms of the PI3 kinase. [Read Article]

B-R doesn’t increase risk of infectious diseases

Erilyn Riley Read Article
Published: 06/21/13

ICML_2013_sign_240.jpg
Attendees at 12-ICML

Results of the StiL NHL7-2008 study indicate that induction therapy with bendamustine and rituximab (B-R) does not increase the risk of infectious diseases in patients with indolent lymphomas. And this is the case despite the resultant severe lymphopenia with low CD4+ and CD8+ counts. Christoph Alexander Burchardt, MD, of the University Hospital Giessen in Germany, presented these data at the 12th International Conference on Malignant Lymphoma. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}